Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

1373 - Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

Date

11 Sep 2017

Session

Gastrointestinal tumours, colorectal 2

Topics

Cytotoxic Therapy;  Translational Research;  Colon and Rectal Cancer

Presenters

Claire Gallois

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

C. Gallois1, J. Taieb2, D. Le Corre3, K. Le Malicot4, J. Tabernero5, C. Mulot3, J. Seitz6, T. Aparicio7, G. Folprecht8, C. Lepage9, E. Mini10, J. Van Laethem11, J.F. Emile12, P. Laurent-Puig13

Author affiliations

  • 1 Department Of Gastroenterology And Digestive Oncology, Hôpital Européen Georges Pompidou, 75000 - Paris/FR
  • 2 Department Of Gastroenterology And Digestive Oncology, Hôpital Européen Georges Pompidou, Paris/FR
  • 3 Department Of Biology, Paris Descartes University, Sorbonne Paris Cité, France; Assistance Publique Hôpitaux de Paris, INSERM-UMR-S1147, Paris/FR
  • 4 Biostatistics, FFCD-, Dijon/FR
  • 5 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Department Of Gastroenterology And Oncology, CHU La Timone, 13385 - Marseille/FR
  • 7 Gastroenterology, Saint Louis Hospital, 75010 - Paris/FR
  • 8 University Cancer Center, Medical Dept. I  , University Hospital Carl Gustav Carus, Dresden  , 01129   - Dresden/DE
  • 9 Gastroenterology, CHU Le Bocage, FFCD, Burgundy University, INSERM U866, 21079 - Dijon/FR
  • 10 Department Of Experimental And Clinical Medicine, University of Florence, Florence/IT
  • 11 Department Of Gastroenterology, Hôpital Universitaire Erasme, Brussels/BE
  • 12 Anatomie Cytologie Pathologiques, Hopital Ambroise Pare, 92100 - Boulogne-Billancourt/FR
  • 13 Department Of Biology, Paris Descartes University, 75006 - Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1373

Background

There are conflicting results concerning the prognostic value of the methylator phenotype (CIMP+ for “CpG island methylator phenotype”) in non-metastatic colon cancer (CC) patients (pts). We studied this phenotype in stage III CC pts having undergone R0 resection, characterized for MSI, RAS and BRAF mutation status and treated with adjuvant FOLFOX-based treatment.

Methods

Tumor samples of 1910 pts enrolled in the PETACC-8 adjuvant phase 3 trial were analysed. The method used was methylation-specific PCR where CIMP+ status was defined by methylation of at least three of the five following genes: IGF2, CACNA1G, NEUROG1, SOCS1 and RUNX3. Association between CIMP status and overall survival (OS), disease-free survival (DFS), and survival after relapse (SAR) was assessed by Cox model and adjusted for prognostic factors (including MSI, BRAF and RAS mutation status) and treatment arm (FOLFOX or FOLFOX plus cetuximab). CIMP status was analyzed according to treatment efficacy.

Results

Determination of CIMP status was successful in 1870 pts (98%): 275 (14.7%) tumors were classified CIMP+. Compared to CIMP- pts, CIMP+ pts were significantly older (p = 0.002), with more frequently women (p = 0.04). CIMP+ tumors were more frequently right-sided (p 

Conclusions

In a large clinically and molecularly well defined stage III CC population treated with standard adjuvant therapy, methylator phenotype is a prognostic biomarker for OS and SAR. However, no impact of CIMP status on DFS was observed. Finally, we did not find any predictive value of the CIMP status for the efficacy of FOLFOX versus FOLFOX plus cetuximab.

Clinical trial identification

PETACC8 Trial (EuDRACT number: 2005-003463-23)

Legal entity responsible for the study

FFCD

Funding

Merck, Sanofi

Disclosure

J. Taieb: Consulting or/and advisory boards: Merck KGaA, Sanofi, Roche Genentech, Pfizer, Amgen. J. Tabernero: Consulting or/and advisory boards: Amgen, ImClone Systems, Lilly, Millennium, Novartis, Roche/Genentech, Sanofi, Celgene, Chugai Pharma, Taiho Pharmaceutical, Boehringer Ingelheim, Merck KGaA. J-F. Seitz: Grants for consultancy: Celgene, Lilly, Merck, Novartis Oncology, Pfizer, Sanofi, Roche; grants: Roche; payments for development of educational presentations: Amgen, Lilly; travel grants: Ipsen Pharma, Merck. T. Aparicio: Personal grants consultancy: Pierre Fabre; grants: Roche, Amgen; payments for development of educational presentations: Novartis Oncology, Pfizer, Sanofi, Roche; travel grants: Ipsen Pharma, Novartis Oncology, Sanofi, Roche. G. Folprecht: Consulting or/and advisory boards: Merck KGaA, Roche/Genentech, Sanofi-Aventis, Bayer, Lilly, Servier, BMS. C. Lepage: Personal grants for board membership: AAA; grants: Novartis; travel grants: Ipsen Pharma, Amgen, Bayer. J.F. Emile: Honoraria: Amgen, Merck KGaA. P. Laurent-Puig: Consulting or/and advisory boards: Sanofi, Merck KGaA, Amgen, Roche, Genomic Health, Myriad Genetics, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.